Literature DB >> 2257219

Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

L M Cobb1, J Nolan, S A Butler.   

Abstract

The tritium-labelled analogues of pimonidazole and RSU 1069 were injected into mice bearing the KHT murine sarcoma which has a hypoxic cell fraction of approximately 10%. The distribution of activity at 24 h was recorded using autoradiography and measurement of tissue activity. Autoradiographs with both drugs showed high activity in particular cells within tumour, eye (melanin-associated cells), eyelid (Meibomian gland), liver (centrilobular area), skin (sebaceous gland and melanin), stomach (squamous area), footpad, oesophagus, labial gland, Zymbal's gland, preputial gland, parotid gland (intralobular ducts) and airway epithelium. These tissues had previously been identified as sites of binding of misonidazole. The measurement of total tissue radioactivity showed significantly higher activity in liver, eyelid (Meibomian gland), oesophageal lining, kidney and labial gland than was found in the tumour.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257219      PMCID: PMC1971577          DOI: 10.1038/bjc.1990.408

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics.

Authors:  J T Roberts; N M Bleehen; M I Walton; P Workman
Journal:  Br J Radiol       Date:  1986-02       Impact factor: 3.039

2.  The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.

Authors:  M I Saunders; P J Anderson; M H Bennett; S Dische; A Minchinton; M R Stratford; M Tothill
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

3.  Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.

Authors:  R J Maxwell; P Workman; J R Griffiths
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

4.  Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin.

Authors:  F Laurent; P Canal; G Soula
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

5.  Pharmacology and toxicology of sensitizers: mechanism studies.

Authors:  A M Rauth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-08       Impact factor: 7.038

6.  Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508.

Authors:  F Lespinasse; C Thomas; M Bonnay; E P Malaise; M Guichard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

7.  Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide).

Authors:  I J Stratford; C Williamson; S Hoe; G E Adams
Journal:  Radiat Res       Date:  1981-12       Impact factor: 2.841

8.  A marker for hypoxic cells in tumours with potential clinical applicability.

Authors:  J D Chapman; A J Franko; J Sharplin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

9.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.

Authors:  I J Stratford; J M Walling; A R Silver
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

View more
  7 in total

Review 1.  Oxygen metabolism and innate immune responses in the gut.

Authors:  Sean P Colgan; Eric L Campbell
Journal:  J Appl Physiol (1985)       Date:  2017-07-13

Review 2.  Oxygen metabolism and barrier regulation in the intestinal mucosa.

Authors:  Louise E Glover; J Scott Lee; Sean P Colgan
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

3.  Hypoxia: A breath of fresh air for the meibomian gland.

Authors:  Yang Liu; Di Chen; Xiaomin Chen; Wendy R Kam; Mark P Hatton; David A Sullivan
Journal:  Ocul Surf       Date:  2018-12-04       Impact factor: 5.033

4.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

5.  Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.

Authors:  R el Gamoussi; M D Threadgill; M Prade; I J Stratford; M Guichard
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

Authors:  M B Parliament; L I Wiebe; A J Franko
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

7.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors:  G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.